Track topics on Twitter Track topics that are important to you
Celltrion, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Celltrion, Inc. - Product Pipeline Review - 2015’, provides an overview of the Celltrion, Inc.’s pharmaceutic...
"Further percolation will not advance the law," Hospira and Celltrion said, insisting that "settling the issue will spur competition."
Contradictory requests from the US FDA on the statistical analysis of Remsima are one of many regulatory hurdles facing biosimilar developers, according to Celltrion.
South Korean biotechnology company Celltrion has, according to Business Korea, submitted a second biosimilar application to the European Medicines Agency (EMA).
Korean drugmaker Celltrion filed for approval from the European Medicines Agency for CT-P10, a biosimilar for the monoclonal -More-
South Korea’s Celltrion has received approval to sell its Remsima from the Ministry of Health of the…
Celltrion contends that since it provided its infliximab biosimilar application to Janssen it doesn’t have to wait until FDA approval to provide 180-day notice of commercial launch.
Data presented at EULAR 2015 show that the effectiveness of Celltrion’s biosimilar infliximab was similar to the RMP in rheumatoid arthritis... The post Data for Celltrion’s biosimilar infliximab ...